Corrigendum to "Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules" [Epilepsy Research 76 (2-3) (2007) 140-147] (DOI:10.1016/j.eplepsyres.2007.07.011);Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules

Epilepsy Research

Volumn 76, Issue 2-3, 2007, Pages 140-147

  Snoeck, Eric ^a   Jacqmin, Philippe ^a   Sargentini Maier, Maria Laura ^b   Stockis, Armel ^b  

^a Exprimo NV   (Belgium)

^b UCB PHARMA   (Belgium)

Author keywords

Epilepsy; Levetiracetam intravenous; NONMEM; Pediatrics; Pharmacokinetics; Simulation

Indexed keywords

ETIRACETAM;

AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; DATA ANALYSIS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG INFUSION; EPILEPSY; EVALUATION; HUMAN; PREDICTION; PRIORITY JOURNAL; SIMULATION; STEADY STATE;

EID: 34548699876     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2007.10.003     Document Type: Erratum

References (26)

1. Baulac M., Brodie M.J., Elger C.E., Krakow K., Stockis A., Meyvisch P., and Falter U. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures. Epilepsia 48 (2007) 589-592
2. In: Beal S.L., and Sheiner L.B. (Eds). NONMEM User's Guide. NONMEM Project Group (1992), University of California at San Francisco, San Francisco
3. Ben-Menachem E., Falter U., and European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41 (2000) 1276-1283
4. Berkovic, S.F., Knowlton, R.C., Leroy, R.F., Schiemann, J., Falter, U., on behalf of the Levetiracetam N01057 Study Group, 2007. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology, E-pub ahead of print at www.neurology.org, in press.
5. Boon P., Chauvel P., Pohlmann-Eden B., Otoul C., and Wroe S. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res. 48 (2002) 77-89
6. Briggs D.E., and French J.A. Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin. Drug Saf. 3 (2004) 415-424
7. Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., Meencke H.J., and Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68 (2007) 402-408
8. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
9. Fountain N.B., Conry J.A., Rodriguez-Leyva I., Gutierrez-Moctezuma J., Salas E., Coupez R., Stockis A., and Lu Z. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4-12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. Epilepsy Res. 74 (2007) 60-69
10. French J., Edrich P., and Cramer J.A. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 47 (2001) 77-90
11. Gidal B.E., Baltes E., Otoul C., and Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res. 64 (2005) 1-11
12. Glauser T.A., Gauer L.J., Lu Z., Van Orman C., Mitchell W., Elterman R., and Ayala R. Short and long-term efficacy of levetiracetam adjunctive therapy in children with refractory partial epilepsy. Epilepsia 46 suppl 6 (2005) 102
13. Glauser T.A., Ayala R., Elterman R.D., Mitchell W.G., Van Orman C.B., Gauer L.J., Lu Z., and and on behalf of the N159 Study Group. Double blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 66 (2006) 1654-1660
14. Glauser T.A., Mitchell W.G., Weinstock A., Bebin E.M., Chen D., Coupez R., Stockis A., and Lu Z. Pharmacokinetics of Levetiracetam in infants and young children with epilepsy. Epilepsia 48 (2007) 1117-1122
15. Johannessen S., Battino D., Berry D., Bialer M., Kramer G., Tomson T., and Patsalos P.N. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit. 25 (2003) 347-363
16. National Center for Health Statistics, 2007. Web site, growth charts. http://www.cdc.gov/growthcharts/.
17. Noachtar, S., Andermann, E., Meyvisch, P., Andermann, F., Gough, W.B., Schiemann-Delgado, J., and the N166 Levetiracetam Study Group, in press. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology.
18. Otoul, C., De Smedt, H., Stockis, A., 2007. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia, doi:10.1111/j.1528-1167.2007.01201.x, in press.
19. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet. 43 (2004) 707-724
20. Pellock J.M., Glauser T.A., Bebin M., Fountain N.B., Ritter F.J., Coupez R.M., and Shields W.D. Pharmacokinetic study of levetiracetam in children. Epilepsia 42 (2001) 1574-1579
21. Perucca E., Gidal B., and Bates E. Effects of Antiepileptic co-medication on Levetiracetam Pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. 53 (2003) 47-56
22. Pigeolet E., Jacqmin P., Sargentini-Maier M.L., and Stockis A. Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clin. Pharmacokin. 46 (2007) 503-512
23. Ramael S., De Smedt F., Toublanc N., Otoul C., Boulanger P., Riethuisen J.M., and Stockis A. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin. Ther. 28 (2006) 734-744
24. Ramael S., Daoust A., Otoul C., Toublanc N., Troenaru M., Lu Z.S., and Stockis A. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 47 (2006) 1128-1135
25. Toublanc N., Jacqmin P., Sargentini-Maier M.L., and Stockis A. Levetiracetam population pharmacokinetics in children with epilepsy. Clin. Pharmacol. Ther. 79 (2006) 19
26. Wade, J.R., Edholm, M., Salmonson, T., 2005. A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective. AAPS J. 7 (article 45). http://www.aapsj.org/view.asp?art=aapsj070245.